---
title: "China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600062.SH.md"
symbol: "600062.SH"
name: "China Resources Double-Crane Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T14:41:57.080Z"
locales:
  - [en](https://longbridge.com/en/quote/600062.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600062.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600062.SH.md)
---

# China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062.SH)

## Company Overview

China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for blood pressure and sugar, injections, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, inflammation, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 and is headquartered in Beijing, the People’s Republic of China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.dcpc.com](https://www.dcpc.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: C (0.41)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 84 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -3.74% |  |
| Net Profit YoY | 0.24% |  |
| P/B Ratio | 1.49 |  |
| Dividend Ratio | 2.72% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 18051457783.67 |  |
| Revenue | 10747750592.96 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 14.11% | B |
| Profit Margin | 15.15% | A |
| Gross Margin | 59.03% | B |
| Revenue YoY | -3.74% | D |
| Net Profit YoY | 0.24% | C |
| Total Assets YoY | 4.15% | C |
| Net Assets YoY | 11.71% | B |
| Cash Flow Margin | 82.64% | C |
| OCF YoY | -3.74% | D |
| Turnover | 0.61 | B |
| Gearing Ratio | 27.79% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - China Resources Double-Crane Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-3.74%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "0.24%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.49",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "2.72%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "18051457783.67",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "10747750592.96",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "14.11%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "15.15%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "59.03%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-3.74%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "0.24%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "4.15%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "11.71%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "82.64%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-3.74%",
          "rating": "D"
        },
        {
          "name": "Turnover",
          "value": "0.61",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "27.79%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 10.95 | 2/215 | 12.71 | 12.28 | 11.91 |
| PB | 1.47 | 40/215 | 1.82 | 1.74 | 1.67 |
| PS (TTM) | 1.66 | 28/215 | 1.82 | 1.77 | 1.74 |
| Dividend Yield | 2.75% | 40/215 | 2.58% | 2.52% | 2.33% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-27T16:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 17.14 |
| Highest Target | 25.65 |
| Lowest Target | 25.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600062.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600062.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600062.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600062.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**